TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31756281
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment for 3 months
Study: 23257975
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg/day)
Study: 27037630
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of fluticasone propionate and salmeterol combinations administered by oral inhalation from three different batches.
Study: 27037630
Drug: Replicated batch
Normalized name: covid-19, viral vector, non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replicated batch administered in two treatment periods.
Study: 20307680
Drug: Pump infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pump infusion system
Study: 20307680
Drug: Gravity infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gravity infusion system
Study: 17941096
Drug: Interpersonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal therapy (IPT)
Study: 393300
Drug: Guanethidine and
Normalized name: guanethidine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanethidine and adrenaline formulation (3.0% and 0.5%)
Study: 393300
Drug: Guanethidine and
Normalized name: guanethidine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanethidine and adrenaline formulation (1.0% and 0.2%)
Study: 19302641
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg.kg(‐1)
Study: 23574713
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid vaginal gel (Hyalofemme)
Study: 23574713
Drug: Estriol cream
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estriol cream (Ovestin)
Study: 18312937
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no infusion)
Study: 15967546
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (15 mg/16 hr)
Study: 14872504
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg once daily
Study: 12907325
Drug: Nonselective NSAIDs
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonselective NSAIDs (ibuprofen, naproxen, or diclofenac)
Study: 10234793
Drug: F-ESWL (fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-ESWL (fragments <= 4 mm, concomitant oral chemolitholysis)
Study: 2062518
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen and 20 mg diazepam
Study: 30700328
Drug: pTVG-HP DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: pTVG-HP DNA vaccine and pembrolizumab
Study: 29532734
Drug: sirukumab 50
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirukumab 50 mg every 4 weeks (q4w)
Study: 29532734
Drug: sirukumab 100
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirukumab 100 mg every 2 weeks (q2w)
Study: 18694046
Drug: Self administered
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self administered questionnaire on computer
Study: 12569085
Drug: C +
Normalized name: Probiotic + Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C + AA (hydrocortisone sodium succinate infusion at 80 microg. kg(‐1). h(‐1))
Study: 12569085
Drug: AA (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA (intravenous saline)
Study: 11126816
Drug: Tropisetron (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (2 mg intravenously at induction)
Study: 9175044
Drug: rHuEpo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo therapy (50 IU/kg intravenously or 35 IU/kg subcutaneously for the first 6 months, then 20 IU/kg)
Study: 9175044
Drug: rHuEpo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo therapy
Study: 3907677
Drug: Oxyfedrine 24
Normalized name: oxyfedrine 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxyfedrine 24 mg four times daily
Study: 29193677
Drug: Gallic Acid
Normalized name: gallic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallic Acid (GA) 15 mg p-1 d-1 for 7 days
Study: 31623572
Drug: Posterior QLB
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior QLB (QLB‐2) using 20 ml 0.25% bupivacaine
Study: 30160789
Drug: Intravenous arsenic
Normalized name: arsenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous arsenic trioxide (ATO)
Study: 30160789
Drug: Oral Realgar-Indigo
Normalized name: indigo
DrugBank: Indigo (DB16862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Realgar-Indigo naturalis formula (RIF)
Study: 27434598
Drug: Cognitive-Behavioral Conjoint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Conjoint Therapy for PTSD (CBCT for PTSD)
Study: 25112087
Drug: Calcium tablets
Normalized name: Leucovorin Calcium Tablets
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium tablets (caltrate, 600 mg per day)
Study: 19436693
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 microg daily
Study: 17226908
Drug: Continuous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous ciprofloxacin treatment (200 mg intravenous injection for 30 min before ERCP and continued until 48 hours after ERCP)
Study: 12086757
Drug: rFGF-2 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFGF-2 (30 microg/kg) on day 1 and placebo on day 30 (single-dose, n=66)
Study: 8594524
Drug: Bausch &
Normalized name: Sodium Chloride Nasal Spray [BAUSCH & LOMB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bausch & Lomb ReNu (multipurpose contact lens care solution)
Study: 21676221
Drug: Lisinopril 5‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 5‐10 mg daily for 7 days
Study: 19366273
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 25 mg ketamine lozenge
Study: 16427197
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma morphine concentrations (173+/‐11 ng/ml)
Study: 10332529
Drug: Computer-based program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based program for identifying drug-related problems
Study: 7418714
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg methotrexate bolus intravenous injection
Study: 7418714
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg methotrexate bolus intravenous injection
Study: 24512733
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C 320 mg/kg
Study: 24512733
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C 480 mg/kg
Study: 3443154
Drug: Fenoterol 5
Normalized name: fenoterol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol 5 mg
Study: 31454351
Drug: Standard RUTF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard RUTF dose throughout treatment
Study: 31454351
Drug: Reduced RUTF
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced RUTF dose after two weeks
Study: 31454351
Drug: Reduced RUTF
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced RUTF dose after two weeks (children under 12 months)
Study: 27472271
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM)
Study: 17109866
Drug: Fenofibrate (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (160 mg/day)
Study: 8027926
Drug: Buccoadhesive tablet
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccoadhesive tablet
Study: 8027926
Drug: Sublingual capsule
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual capsule
Study: 2644962
Drug: Amethocaine preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amethocaine preparation (0.5 g applied for 30 min)
Study: 2644962
Drug: Eutectic Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eutectic Mixture of Local Anaesthetics (EMLA) (2.5 g applied for 60 min under an occlusive dressing)
Study: 2644962
Drug: Amethocaine preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amethocaine preparation vs EMLA
Study: 53598
Drug: Twice-weekly isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly isoniazid 15 mg/kg plus rifampicin 900 mg (HR2 regimen)
Study: 53598
Drug: Twice-weekly isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly isoniazid 15 mg/kg plus rifampicin 600 mg (LR2 regimen)
Study: 53598
Drug: Once-weekly isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly isoniazid 15 mg/kg plus rifampicin 900 mg (HR1 regimen)
Study: 53598
Drug: Once-weekly isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly isoniazid 15 mg/kg plus rifampicin 600 mg (LR1 regimen)
Study: 53598
Drug: Rifampicin 25
Normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 25 mg supplement
Study: 31276986
Drug: Enhanced profile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced profile with graphical representation of prescriptions and identified risky prescribing patterns
Study: 26117150
Drug: Self-administered LAIV
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered LAIV (SA)
Study: 26117150
Drug: Healthcare worker-administered
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthcare worker-administered LAIV (HCWA)
Study: 26117150
Drug: Self-administration (SA)
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administration (SA)
Study: 8522638
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg orally once daily for 6 days
Study: 2185026
Drug: Surfactant (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (100 mg phospholipid/kg, 4 ml/kg)
Study: 2185026
Drug: Air (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air (4 ml/kg)
Study: 349091
Drug: Cefamandole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (500 mg every 8 hr for 7 days)
Study: 349091
Drug: Cefazolin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (500 mg every 8 hr for 7 days)
Study: 27230855
Drug: 1 mg/d
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/d rasagiline
Study: 25230559
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group (no antioxidants, drugs, vitamins or dietary supplements)
Study: 19394598
Drug: Doxycycline 20
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 20 mg orally twice a day after LNG-SI insertion
Study: 19394598
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally twice a day after LNG-SI insertion
Study: 22873680
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg every 12 hours plus fluvoxamine
Study: 1627428
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (XRT) with full axillary dissection and gross removal of the tumor, followed by 4500 to 5000 cGy to the whole breast and a boost to the tumor bed of 1500 to 2000 cGy; patients with positive axillary dissections also received cyclophosphamide and doxorubicin
Study: 30674240
Drug: Valganciclovir 450
Normalized name: valganciclovir 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir 450 mg daily (group 1)
Study: 30674240
Drug: Valganciclovir 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir 900 mg daily (group 2)
Study: 26034151
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly
Study: 23016508
Drug: Intramuscular progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intramuscular progesterone (250 mg weekly)
Study: 12036265
Drug: Adaptive two-stage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive two-stage dose-response trial
Study: 12036265
Drug: Loss-function based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loss-function based approach for dose selection
Study: 12036265
Drug: Adaptive two-stage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive two-stage designs with dose-selection rule
Study: 8486515
Drug: Streptomycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin (1 g) with 2% lidocaine (3 ml)
Study: 8486515
Drug: Lidocaine alone
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine alone (3 ml)
Study: 2444395
Drug: Topical glucocorticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glucocorticosteroid (flumethasone pivalate 0.02 percent)
Study: 2444395
Drug: Aqueous solution
Normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous solution of eosin 2 percent
Study: 30281180
Drug: Oral chloral
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral chloral hydrate at 50 mg kg-1
Study: 20395941
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) therapy with losartan
Study: 20395941
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) therapy with atenolol
Study: 15704099
Drug: EFL group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFL group (40 teeth treated with fluoride gel and lased)
Study: 15704099
Drug: EF group
Normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EF group (40 teeth treated with fluoride gel)
Study: 12590404
Drug: Clomipramine (100-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (100-250 mg/day)
Study: 18369175
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and extended-release dipyridamole
Study: 19924412
Drug: Post-chemotherapy values
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-chemotherapy values
Study: 2268639
Drug: Conservative stomatological
Normalized name: STOMATOLOGICAL PREPARATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative stomatological treatment with beta-adrenergic blocking agent 'Obsidan'
Study: 85006
Drug: Chemotherapy as
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy as the only treatment
Study: 85006
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus local irradiation
Study: 85006
Drug: Chemotherapy (Doxorubicin‐containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Doxorubicin‐containing drug regimens)
Study: 26606200
Drug: 60-Gy radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-Gy radiation therapy (RT) with concurrent and consolidation carboplatin/paclitaxel
Study: 17685720
Drug: Protease supplement
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease supplement
Study: 15807275
Drug: haiguiyuyang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: haiguiyuyang capsule
Study: 8141101
Drug: Ftorafur, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ftorafur, 400 mg/m2/day and Tamoxifen, 20 mg/day (Group B)
Study: 3051673
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg twice a day)
Study: 28545491
Drug: TESI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TESI plus Levobupivacaine added to oral pain medication
Study: 28545491
Drug: Transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal epidural injection (TEI) with Levobupivacaine and saline solution added to oral pain medication
Study: 28545491
Drug: Oral pain
Normalized name: Oral Pain Relief
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pain medication
Study: 19936527
Drug: PA +
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA + AS (35% phosphoric acid gel + adhesive system)
Study: 17014560
Drug: Combined low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined low-dose tacrolimus (2 mg/day) and prednisone (30 mg/day)
Study: 17014560
Drug: Prednisone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (1 mg/kg per day)
Study: 28628402
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement
Study: 3802729
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet every six hours, beginning two days before lidocaine administration
Study: 27501015
Drug: Pudendal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudendal block (0.25% bupivacaine 0.5 mL/kg)
Study: 27501015
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block (0.2% bupivacaine 1 mL/kg)
Study: 24316514
Drug: Serelaxin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serelaxin (30 μg/kg/day for 48 hours)
Study: 19737595
Drug: 37% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37% phosphoric acid gel (H(3)PO(4)) for 120s
Study: 1718477
Drug: Morphine, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine, 1 mg/kg
Study: 1718477
Drug: Oxymorphone, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone, 0.2 mg/kg
Study: 11422884
Drug: Melatonin 6
Normalized name: melatonin 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 6 mg
Study: 15677607
Drug: ondansetron (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (16 mg)
Study: 2904751
Drug: Overall doxazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall doxazosin therapy
Study: 2904751
Drug: Doxazosin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin therapy
Study: 26553313
Drug: Escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 20 mg/day for 52 weeks
Study: 7534239
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 micrograms) administered subcutaneously
Study: 27471804
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel (CHX), two applications with one-week interval
Study: 21162925
Drug: No thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thrombolytic therapy (for Group C)
Study: 17926468
Drug: Enalapril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (mean dose 21.9 +/- 9.0 mg/day) with adjuvant indapamide (2.5 mg/day)
Study: 3522040
Drug: iohexol 240
Normalized name: iohexol 240 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 240 mg I/ml
Study: 2207773
Drug: Higher concentration
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher concentration of iohexol (300 mg I/ml)
Study: 2207773
Drug: Lower concentration
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower concentration of iohexol (240 mg I/ml)
Study: 18534496
Drug: High-dose continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose continuous FNB
Study: 18534496
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous FNB
Study: 3559150
Drug: PK 8165
Normalized name: Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PK 8165 (pipequaline) 50 mg
Study: 24679633
Drug: Rituximab with
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab with bevacizumab (10 mg/kg I.V. on days 3 and 15)
Study: 24679633
Drug: Rituximab alone
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab alone (375 mg/m(2) I.V. weekly for 4 weeks)
Study: 16192516
Drug: PPI (rabeprazol
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI (rabeprazol 20 mg)
Study: 16192516
Drug: H2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 group (roxatidine 75 mg)
Study: 12523578
Drug: Oral valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valacyclovir (VAL), 1 g orally every 12 hours from day 0 to engraftment
Study: 12523578
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir (ACY), 250 mg/m2 intravenously every 12 hours from day 0 to engraftment
Study: 6262206
Drug: FK 33-824,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK 33-824, 0.5 mg i.m.
Study: 15605688
Drug: Cefuroxime axetil/Pharmathen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime axetil/Pharmathen (test preparation)
Study: 13937554
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 16% antivaccinia gamma-globulin (AGG)